Sunday, November 22, 2026
27.7 C
Bengaluru

Indian Pharma Regional Performance Analysis & Summary

Overall Market Performance (IPM)
• The Indian Pharmaceutical Market (IPM) recorded a total value of ₹229,260.6 crore, with an overall growth of 7.6% for Dec’24.
• Out of 26 regions, 12 states/regions grew faster than the IPM growth rate of 7.6%, while the rest grew equal to or slower.

Regional Zone-Wise Performance
1. North Zone (₹62,928.3 Cr, 27% MS, 8.0% Growth)
• Top Contributors: Uttar Pradesh (₹25,550.2 Cr, 41% MS), Delhi (₹10,756.3 Cr, 17% MS).
• Fastest Growing: Delhi (12.5%), Jammu & Kashmir (9.4%), Haryana (8.8%).
2. South Zone (₹60,758.9 Cr, 27% MS, 7.1% Growth)
• Top Contributors: Karnataka (₹13,486.8 Cr, 22% MS), Tamil Nadu (₹11,509.0 Cr, 19% MS).
• Fastest Growing: Chennai (11.6%), Telangana (8.9%), Tamil Nadu (8.2%).
3. East Zone (₹56,501.1 Cr, 25% MS, 7.4% Growth)
• Top Contributors: West Bengal (₹14,651.3 Cr, 26% MS), Bihar (₹12,078.9 Cr, 21% MS).
• Fastest Growing: Chhattisgarh (9.5%), Orissa (8.7%), Assam (7.6%).
4. West Zone (₹49,072.3 Cr, 21% MS, 8.0% Growth)
• Top Contributors: Maharashtra (₹19,780.5 Cr, 40% MS), Madhya Pradesh (₹10,154.7 Cr, 21% MS).
• Fastest Growing: Madhya Pradesh (9.8%), Maharashtra (8.6%), Gujarat (8.7%).

Key Highlights

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Topics

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...
spot_img

Related Articles

spot_imgspot_img